Navigating the tumor microenvironment: mesenchymal stem cell-mediated delivery of anticancer agents

Scientific knowledge of cancer has advanced greatly throughout the years, with most recent studies findings includes many hallmarks that capture disease's multifaceted character. One of the novel approach utilised for the delivery of anti-cancer agents includes mesenchymal stem cell mediated dr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of drug targeting 2024-07, Vol.32 (6), p.624-634
Main Authors: Waqar, Muhammad Ahsan, Zaman, Muhammad, Khan, Rabeel, Shafeeq Ur Rahman, Muhammad, Majeed, Imtiaz
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - administration & dosage
Drug Delivery Systems
Humans
Mesenchymal Stem Cell Transplantation - methods
Mesenchymal Stem Cells
Neoplasms - drug therapy
Neoplasms - therapy
Tumor Microenvironment - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Scientific knowledge of cancer has advanced greatly throughout the years, with most recent studies findings includes many hallmarks that capture disease's multifaceted character. One of the novel approach utilised for the delivery of anti-cancer agents includes mesenchymal stem cell mediated drug delivery. Mesenchymal stem cells (MSCs) are non-haematopoietic progenitor cells that may be extracted from bone marrow, tooth pulp, adipose tissue and placenta/umbilical cord blood dealing with adult stem cells. MSCs are mostly involved in regeneration of tissue, they have also been shown to preferentially migrate to location of several types of tumour . Usage of MSCs ought to improve both effectiveness and safety of anti-cancer drugs by enhancing delivery efficiency of anti-cancer therapies to tumour site. Numerous researches has demonstrated that various drugs, when delivered mesenchymal stem cell mediated delivery can elicit anti-tumour effect of cells in cancers of breast cells and thyroid cells. MSCs have minimal immunogenicity because to lack of co-stimulatory molecule expression, which means there is no requirement for immunosuppression after allogenic transplantation. This current review elaborates recent advancements of mesenchyma stem cell mediated drug delivery of anti-cancer agents along with its mechanism and previously reported studies of drugs manufactured this drug delivery system.
ISSN:1061-186X
1029-2330
1029-2330
DOI:10.1080/1061186X.2024.2347356